Features

Merck KGaA Chair and CEO Belén Garijo is coming on board as Sanofi’s new CEO next week, succeeding former CEO Paul Hudson, who stepped down in February. The company reported its first quarter results this week? What products—commercial and pipeline will drive growth?

Almost 40 European, national, and regional industry organizations have signed a joint position paper to support the European Union’s Biotech Act II, an initiative to boost capacity and innovation in biomanufacturing in the EU. What does it mean for the bio/pharma industry?

Novo Nordisk is the latest pharmaceutical major to partner directly with a high-tech giant to advance AI in their operations, including for drug development, manufacturing, and the supply chain. A roundup of the latest partnerships and projects.

An upcoming DCAT conference, The DCAT Global Summit 2026: The Future of Bio/Pharma: Mastering the Supply Chain, Digitalization & Global Shifts, June 10-11, in Sitges, Barcelona, Spain, will provide executive perspectives on AI and digital transformation across the bio/pharmaceutical value chain.

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

What other DCAT Member Companies are making news from DCAT Week? A roundup of the latest developments from suppliers and CDMOs/CMOs.

The education programs at DCAT Week 2026, held March 23–26, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the pharma customer–supplier relationship.

Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).

Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.

The bio/pharma industry faces geopolitical uncertainties, fluid trade conditions, and greater product and supply-chain complexity. What lies ahead for bio/pharma companies and suppliers? An outlook for the industry.